Hull M E, Moghissi K S, Magyar D F, Hayes M F
Fertil Steril. 1987 Jan;47(1):40-4.
This study was designed to evaluate the effectiveness of three therapeutic modalities in the management of stage I and II endometriosis. Management modalities consisted of no treatment (controls, n = 56); oral medroxyprogesterone acetate (MPA), 30 mg orally per day for 90 days (n = 36); and danazol, 600 to 800 mg daily for 6 months (n = 52). All patients were followed for at least 18 months of exposure to pregnancy. Cumulative pregnancy rates were determined by life-table analysis. At 30 months, pregnancies resulted in 55% of group I (controls), 71% of group II (MPA), and 46% of group III (danazol). There were no significant differences among these rates. Similarly, there was no significant difference between the cumulative pregnancy rates for stage I (59%) and for stage II (57%). Abortion rates for the various treatment modalities were the following: MPA 6.3%, danazol 11%, and no treatment, 14.3%. The spontaneous abortion rate in stage I and stage II disease was not significantly different. The results of this study suggest that a period of expectant management with correction of other infertility factors may be warranted in patients with mild to moderate endometriosis before medical therapy is contemplated.
本研究旨在评估三种治疗方式对Ⅰ期和Ⅱ期子宫内膜异位症的治疗效果。治疗方式包括不治疗(对照组,n = 56);口服醋酸甲羟孕酮(MPA),每天30 mg,共90天(n = 36);以及达那唑,每天600至800 mg,共6个月(n = 52)。所有患者均随访至少18个月直至妊娠。累积妊娠率通过寿命表分析确定。30个月时,Ⅰ组(对照组)的妊娠率为55%,Ⅱ组(MPA)为71%,Ⅲ组(达那唑)为46%。这些比率之间无显著差异。同样,Ⅰ期(59%)和Ⅱ期(57%)的累积妊娠率之间也无显著差异。各种治疗方式的流产率如下:MPA为6.3%,达那唑为11%,不治疗为14.3%。Ⅰ期和Ⅱ期疾病的自然流产率无显著差异。本研究结果表明,对于轻度至中度子宫内膜异位症患者,在考虑药物治疗之前,可能有必要进行一段时间的期待治疗并纠正其他不孕因素。